We have located links that may give you full text access.
Inflammation and cardiovascular disease in familial Mediterranean fever. An analysis of hospital admissions for acute cardiovascular event.
Clinical and Experimental Rheumatology 2018 September 28
OBJECTIVES: Patients, suffering from inflammatory disorders, are at an increased risk to develop cardiovascular disease (CVD). Here, we examine whether in familial Mediterranean fever (FMF), a model of inflammatory diseases, inflammation also increases the risk to develop cardiovascular (CV) disease.
METHODS: To explore the role of inflammation in the occurrence of CVD in FMF, we identified all FMF patients ≤55 years old with CVD, admitted to our center over a 15-year period. Correlates of inflammation, such as severity of FMF and dose of colchicine, as well as the presence of traditional CV risk factors were compared between the FMF patients with CVD (FMF- CVD) and control FMF patients with- out CVD.
RESULTS: Twenty-three FMF-CVD and 40 control patients were compared. The severity of FMF, and the dose of colchicine, were similar in the 2 study groups; therefore, not associated with CVD. Compared with FMF patients without CVD, the FMF-CVD group comprised a higher proportion of men (78 vs. 40% p=0.005), and of patients with diabetes (31 vs. 7%, p=0.016) and inflammatory comorbidities such as Behçet's disease (30 vs. 7%, p=0.005). Multivariate analysis revealed that only diabetes mellitus and inflammatory comorbidities were independent factors associated with FMF-CVD.
CONCLUSIONS: In FMF patients treated with colchicine, CVD is not associated with FMF-related inflammation.
METHODS: To explore the role of inflammation in the occurrence of CVD in FMF, we identified all FMF patients ≤55 years old with CVD, admitted to our center over a 15-year period. Correlates of inflammation, such as severity of FMF and dose of colchicine, as well as the presence of traditional CV risk factors were compared between the FMF patients with CVD (FMF- CVD) and control FMF patients with- out CVD.
RESULTS: Twenty-three FMF-CVD and 40 control patients were compared. The severity of FMF, and the dose of colchicine, were similar in the 2 study groups; therefore, not associated with CVD. Compared with FMF patients without CVD, the FMF-CVD group comprised a higher proportion of men (78 vs. 40% p=0.005), and of patients with diabetes (31 vs. 7%, p=0.016) and inflammatory comorbidities such as Behçet's disease (30 vs. 7%, p=0.005). Multivariate analysis revealed that only diabetes mellitus and inflammatory comorbidities were independent factors associated with FMF-CVD.
CONCLUSIONS: In FMF patients treated with colchicine, CVD is not associated with FMF-related inflammation.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app